FDA Approves UCB's RYSTIGGO as First Drug for Myasthenia Gravis Treatment
The FDA has approved UCB's Rystiggo, a treatment for generalized myasthenia gravis, making it the first drug to receive approval for both main subtypes of the rare autoimmune disease. UCB plans to make the under-the-skin treatment commercially available in the third quarter, following the recent approval of argenx's Vyvgart Hytrulo in subcutaneous form.